Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYWV81)

Drug Name
EPI-001 Drug Info
Synonyms
227947-06-0; BADGE-HCl-H2O; Bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether; 3-[4-[2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl]phenoxy]propane-1,2-diol; 3-(4-{2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl}phenoxy)propane-1,2-diol; EPI 001; AC1N56RN; SCHEMBL12267194; CTK8F8201; CHEBI:59642; DTXSID30400170; MolPort-003-939-733; BCP18361; EX-A2389; s7955; AKOS030573303; ACM227947060; AC-29035; RT-011557; EPI-001, > J-014857
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Investigative [1]
Cross-matching ID
PubChem CID
4166922
ChEBI ID
CHEBI:59642
CAS Number
CAS 227947-06-0
TTD Drug ID
DMYWV81

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Androgen receptor (AR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [3]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [4]
Darolutamide DMV7YFT Prostate cancer 2C82.0 Approved [5]
Testosterone DM7HUNW Hot flushes GA30 Approved [6]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [7]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [8]
Fludrocortisone DMUDIR8 Addison disease 5A74.0 Approved [9]
ARN-509 DMT81LZ Acute myeloid leukaemia 2A60 Approved [10]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [11]
Nandrolone DMFWKG1 Osteoporosis FB83.0 Approved [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prostate-specific antigen (KLK3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [13]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [14]
Selenium DM25CGV N. A. N. A. Approved [15]
Quercetin DM3NC4M Obesity 5B81 Approved [16]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [1]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [17]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [18]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [19]
Testosterone DM7HUNW Hot flushes GA30 Approved [20]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [22]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [23]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [24]
Gefitinib DM15F0X Colon adenocarcinoma Approved [25]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [26]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [27]
Etretinate DM2CZFA Keratosis ED56 Approved [28]
Prednisone DM2HG4X Acute asthma CA23 Approved [29]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [30]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [32]
Gefitinib DM15F0X Colon adenocarcinoma Approved [33]
Prednisone DM2HG4X Acute asthma CA23 Approved [29]
Methotrexate DM2TEOL Anterior urethra cancer Approved [34]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [35]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [36]
Quercetin DM3NC4M Obesity 5B81 Approved [37]
Fluoxetine DM3PD2C Bipolar depression Approved [38]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [39]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By kinase isozyme 4, mitochondrial (PDK4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [41]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [42]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [44]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [45]
Clodronate DM9Y6X7 Hypercalcaemia 5B91.0 Approved [45]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [45]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [46]
Testosterone enanthate DMB6871 N. A. N. A. Approved [47]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lipid transferase CIDEC (CIDEC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [49]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [50]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [46]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [51]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [52]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [53]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [54]
DNCB DMDTVYC Immune System disease 4A01-4B41 Phase 2 [55]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [49]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Thyroid hormone receptor beta (THRB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [57]
Panobinostat DM58WKG Chronic graft versus host disease Approved [58]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [59]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [60]
Testosterone DM7HUNW Hot flushes GA30 Approved [61]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [62]
Leflunomide DMR8ONJ Arthritis FA20 Approved [63]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [64]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [51]
Ethanol DMDRQZU Chronic pain MG30 Approved [65]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Modulator [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [1]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Gene/Protein Processing [1]
kinase isozyme 4, mitochondrial (PDK4) OTCMHMBZ PDK4_HUMAN Gene/Protein Processing [1]
Lipid transferase CIDEC (CIDEC) OTMDZ56K CIDEC_HUMAN Gene/Protein Processing [1]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Gene/Protein Processing [1]
Thioredoxin-interacting protein OT46QN4B TXNIP_HUMAN Gene/Protein Processing [1]
Thyroid hormone receptor beta (THRB) OTBBIRHZ THB_HUMAN Protein Interaction/Cellular Processes [2]

References

1 EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
2 Identification and Molecular Interaction Studies of Thyroid Hormone Receptor Disruptors among Household Dust Contaminants. Chem Res Toxicol. 2016 Aug 15;29(8):1345-54. doi: 10.1021/acs.chemrestox.6b00171. Epub 2016 Aug 2.
3 Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
4 Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
6 Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
7 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
8 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
9 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
10 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
11 CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
12 Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
13 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
14 Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim Acta. 2001 Oct;312(1-2):213-9. doi: 10.1016/s0009-8981(01)00626-x.
15 Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
16 Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
17 Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 2007 Aug 1;67(11):1152-62. doi: 10.1002/pros.20585.
18 Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
19 An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817.
20 Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
21 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
22 Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
23 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
24 Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
25 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
26 BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
27 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
28 Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
29 Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
30 Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
31 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
32 Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
33 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
34 Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
35 Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
36 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
37 Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
38 Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
39 Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
40 Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
41 Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
42 The PPAR gamma agonist troglitazone induces musclin mRNA expression in human myotubes. Horm Metab Res. 2006 Sep;38(9):614-6. doi: 10.1055/s-2006-951310.
43 Retinoic acids and trichostatin A (TSA), a histone deacetylase inhibitor, induce human pyruvate dehydrogenase kinase 4 (PDK4) gene expression. Biochim Biophys Acta. 2006 Mar-Apr;1759(3-4):141-51. doi: 10.1016/j.bbaexp.2006.04.005. Epub 2006 Apr 27.
44 Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid hormone. J Biol Chem. 2013 Jan 11;288(2):807-18. doi: 10.1074/jbc.M112.437970. Epub 2012 Dec 3.
45 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
46 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
47 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
48 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
49 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
50 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
51 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
52 Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab. 2007 Feb;92(2):720-4.
53 Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
54 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
55 Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol. 2007 May;44(12):3222-33.
56 Microarray analysis of bisphenol A-induced changes in gene expression in human oral epithelial cells. Acta Biochim Biophys Sin (Shanghai). 2007 Nov;39(11):879-84. doi: 10.1111/j.1745-7270.2007.00351.x.
57 Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
58 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
59 Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem. 2002 Jul 18;45(15):3310-20. doi: 10.1021/jm0201013.
60 Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
61 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
62 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
63 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
64 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
65 Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.